Abstract
To evaluate the efficacy and safety of a combined regimen of bendamustine (B) and rituximab (R) in Japanese patients with relapsed/refractory (r/r) indolent B-cell non-Hodgkin lymphomas (B-NHLs) and mantle cell lymphoma (MCL). Patients aged 20-79 years with pathologically confirmed B-NHLs or MCL, which were r/r after 1-2 R-containing regimens, were included in this study. The BR regimen consisted of B (90 mg/m(2)) for two consecutive days and R (375 mg/m(2)) on day 1, 2, or 3. The course was repeated every 4 weeks for up to four cycles. Fifty-three patients were enrolled in this study and analyzed. The diagnosis included follicular lymphoma (FL) (77 %), mucosa-associated lymphoid tissue lymphoma (13 %) and others (10 %). Forty-seven (90 %) patients completed four cycles of treatment as per schedule. Best overall response rate (ORR) and complete response rate (CRR) was 94 and 71 %, respectively (for FL, ORR 95 % and CRR 80 %). The treatment was well tolerated and the primary toxicity was myelosuppression; the incidence of grade 3/4 leukopenia and neutropenia were 42 and 40 %, respectively. There were no grade 5 toxicities. The BR regimen is safe in Japanese patients with r/r indolent B-NHLs and MCL, and is effective for those wi...Continue Reading
References
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Y BastionB Coiffier
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Oct 1, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harry C SchoutenGunnar Kvalheim
Nov 16, 2004·International Journal of Hematology·Michinori OguraUNKNOWN Cladribine Study Group
May 24, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mathias J RummelParis S Mitrou
Dec 7, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kensei TobinaiTomomitsu Hotta
May 2, 2007·Journal of the National Cancer Institute·Holger SchulzAndreas Engert
Jul 16, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K Sue RobinsonBruce D Cheson
Oct 8, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Abdulwahab J Al-TourahJoseph M Connors
Nov 21, 2008·Cancer Science·Kensei TobinaiKeigo Endo
Mar 13, 2010·Clinical Lymphoma, Myeloma & Leukemia·Bruce D ChesonMathias Rummel
Jul 3, 2010·Cancer Science·Michinori OguraUNKNOWN Japanese Bendamustine Lymphoma Study Group
Jul 16, 2010·Cancer Science·Ken OhmachiUNKNOWN Japanese Bendamustine Lymphoma Study Group
Oct 15, 2010·European Journal of Haematology·Sari RiihijärviSirpa Leppä
Apr 19, 2012·Haematologica·Ulrich JägerUNKNOWN Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT) Investigators
Nov 16, 2012·Leukemia & Lymphoma·Rudolf WeideHubert Köppler
Jan 9, 2014·Hepatology Research : the Official Journal of the Japan Society of Hepatology·UNKNOWN Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology
Citations
Sep 29, 2015·Leukemia & Lymphoma·Sung Yong OhCheolwon Suh
Dec 6, 2018·Leukemia & Lymphoma·Antonio RuedaMariano Provencio
Jun 14, 2018·The Oncologist·Haige YeMichael L Wang
Mar 3, 2020·Biological & Pharmaceutical Bulletin·Shigeru IshidaNobuaki Egashira
Jun 4, 2019·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Hiroyuki WatanabeSatohiro Masuda
May 28, 2019·International Journal of Hematology·Yosuke MatsumotoUNKNOWN Kyoto Clinical Hematology Study Group (KOTOSG)
Mar 21, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jacob D SoumeraiJohn F Gerecitano
Feb 27, 2021·Deutsches Ärzteblatt International·Anna ZoellnerWolfgang Hiddemann